Meeting
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort B of the phase 1b/2 KEYNOTE-365 study.
Authors
Christophe Massard
Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France
Christophe Massard , Margitta Retz , Peter Hammerer , Fernando Quevedo , Peter C.C. Fong , William R. Berry , Howard Gurney , Josep M. Piulats , Anthony M. Joshua , Mark David Linch , Michael Paul Kolinsky , Emanuela Romano , Srikala S. Sridhar , Henry Jacob Conter , Marinela Augustin , Helen Wu , Charles Schloss , Christian Heinrich Poehlein , Evan Y. Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT02861573
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5029)
DOI
10.1200/JCO.2019.37.15_suppl.5029
Abstract #
5029
Poster Bd #
141
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).
First Author: Christophe Massard
Poster
2023 ASCO Genitourinary Cancers Symposium
Racial differences in survival and healthcare resource utilization among Medicaid-insured adults with metastatic castration-resistant prostate cancer.
First Author: Maral DerSarkissian
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2020 ASCO Virtual Scientific Program
Radiographic paradoxical response in patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with second-generation hormone therapy (second-HT).
First Author: Jamal Alamiri